Das Bild zeigt eine Ärztin am Schreibtisch im Gespräch mit einem Mann und einer Frau.

Veröffentlichungen

Sie befinden sich hier:

Anbei finden Sie einige unserer Veröffentlichungen zum Thema Nierenzell-Karzinom.

Publikationen Stand 10.07.2017

Originalarbeiten

Flörcken A, Johannsen M, Nguyen-Hoai T, Wagner A-C, Gerhardt A, Miller K, Dörken B, Pezzutto A, Westermann J und Joehrens K. Immunomodulatory molecules in renal cell cancer: CD80 and CD86 are expressed on tumor cells. International Journal of Clinical and Experimental Pathology 2017;10(2):1443-1454.

Flörcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, Dörken B, Pezzutto A, Westermann J. Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Immunology Letters 2015, 168(2):260-7

Flörcken A, Grau M, Wolf A , Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J. Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: Tumor-induced immunosuppression and a possible role for NF-kB. International Journal of Cancer 2015,136(8):1814-26.

Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Human Vaccines & Immunotherapeutics 2013, 9(6): 1217-27.

Flörcken A, Takvorian A, van Lessen A, Singh A, Hopfenmueller W, Dörken B, Pezzutto A, Westermann J. Sorafenib, but not sunitinib induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anti-Cancer Drugs 2012, 23:298-302.

Johannsen M, Flörcken A (geteilte Erstautorenschaft), Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. European Urology 2009, 55(6):1430-8.

Ralla B, Erber B, Goranova I, von der Aue L, Flörcken A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J. Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. World Journal of Urology. 2015 Dec 16. [Epub ahead of print]

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology 2015, 68(5):837-47.

Geisel D, Collettini F, Denecke T, Grieser C, Flörcken A, Wust P, Hamm B, Gebauer B. Treatment for liver metastasis from renal cell carcinoma with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT): a case series. World Journal of Urology 2013, 31(6): 1525-30.

Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World Journal of Urology 2013, 31(4):805-9.

Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A. Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Therapy 2011, 18(4):354-63.

Johannsen M, Staehler M, Ohlmann CH, Flörcken A, Schmittel A, Otto T, Bex A, Hein P, Miller K, Weikert S, Grünwald V. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Annals of Oncology 2011, 22(3):657-63.

Westermann J, Hecker AC, Flörcken A, Dörken B, Pezzutto A. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome. Journal of Immunotherapy 2009, 22(6):667-75.

 

Fallbeschreibungen

Flörcken A, Loew A, Koch M, Gebauer B, Dörken B, Riess H. Severe thrombocytopenia in a patient with metastatic renal cell carcinoma. Onkologie 2009, 32(11):670-2.

Flörcken A, Denecke T, Kretzschmar A, Gollasch H, Reich G, Westermann. Long lasting remission of pulmonary metastases of renal cell cancer under IFN-ß therapy in a patient with multiple sclerosis. Onkologie 2006, 29(8-9):382-4